Wednesday, August 6, 2025
Tuesday, August 5, 2025
TransMedics Group (TMDX) : 6-year performance
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
- Sector: Healthcare
- Industry: Medical Devices
- Full Time Employees: 728
- Founded in 1998
- Headquartered in Andover, Massachusetts.
- https://www.transmedics.com
TransMedics is in the business of providing the technology for organ transplants. Its Organ Care System (OCS) allows donor organs to be preserved in a living and functioning state by supplying oxygenated blood while they are being transported.
The OCS system sidesteps the limitations of using ice to transport organs such as the heart, liver or lungs. Organs placed in ice for extended periods of time are at risk of being damaged. According to the company, the OCS method has an added advantage since the system allows doctors to assess the organ's viability – something that is difficult to do when the organ is metabolically inactive in cold storage.
On Monday, shares rose 7%, extending a winning streak to four days after the FDA gave an investigational device exemption for OCS in a new clinical trial for heart transplants. The two-phase trial will test longer perfusion time (passage of blood) for heart transplants using OCS and assess the system's ability to support heart transplants from donors after brain death. The trial is expected to exceed 650 patients and may be the largest clinical trial conducted for heart preservation for transplant purposes.
Subscribe to:
Posts (Atom)